Aurora Cannabis (NASDAQ:ACB) has entered the final stage of production trials for a new generation of cannabis cultivars designed to be naturally immune to powdery mildew, a breakthrough that could eliminate one of the industry's most expensive cultivation risks.
Nearly a year after identifying the unique "PM2" genetic resistance source, the Edmonton-based company confirmed Wednesday that it has successfully integrated the trait into its elite breeding lines.
Powdery mildew is a pervasive fungal threat that can destroy 15% or more of a crop’s value, leading to significant yield losses and failed lab tests for mold.
By utilizing a proprietary genetic marker technology developed at its "Aurora Coast" R&D facility, Aurora has been able to track the PM2 gene across multiple generations of crosses.
The company is currently running high-pressure infection trials at its Aurora Ridge facility to ensure the resistance holds up in a commercial greenhouse environment without degrading THC levels or terpene profiles.
The PM2 research, which grew out of a long-term collaboration with the University of British Columbia and received funding from Genome British Columbia, is currently patent-pending in multiple global jurisdictions.
Aurora has indicated it may explore licensing the PM2-resistant genetics to other licensed producers, creating a potential high-margin recurring revenue stream.
If current production trials meet quality benchmarks, Aurora plans to launch the first PM-resistant medical and consumer cultivars in Canada and Europe later this year.